TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial

Francesco Sclafani, David Gonzalez, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Alice Dewdney, Andrew Wotherspoon, Gina Brown, Diana Tait, Jacqueline Oates, Ian Chau

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

In this updated analysis of the EXPERT-C trial we show that, in magnetic resonance imaging-defined, high-risk, locally advanced rectal cancer, adding cetuximab to a treatment strategy with neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX is not associated with a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in both KRAS/BRAF wild-type and unselected patients. In a retrospective biomarker analysis, TP53 was not prognostic but emerged as an independent predictive biomarker for cetuximab benefit. After a median follow-up of 65.0 months, TP53 wild-type patients (n = 69) who received cetuximab had a statistically significant better PFS (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P =. 02 by Cox regression) and OS (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P =. 02 by Cox regression) than TP53 wild-type patients who were treated in the control arm. An interaction between TP53 status and cetuximab effect was found (P <. 05) and remained statistically significant after adjusting for statistically significant prognostic factors and KRAS. © 2014 The Author 2014. Published by Oxford University Press. All rights reserved.
Original languageEnglish
Article numberdju121
JournalJournal of the National Cancer Institute
Volume106
Issue number7
DOIs
Publication statusPublished - 9 Jul 2014

Fingerprint Dive into the research topics of 'TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial'. Together they form a unique fingerprint.

  • Cite this

    Sclafani, F., Gonzalez, D., Cunningham, D., Hulkki Wilson, S., Peckitt, C., Tabernero, J., Glimelius, B., Cervantes, A., Dewdney, A., Wotherspoon, A., Brown, G., Tait, D., Oates, J., & Chau, I. (2014). TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. Journal of the National Cancer Institute, 106(7), [dju121]. https://doi.org/10.1093/jnci/dju121